Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting

InVivo Therapeutics Holdings Corp.
Posted on: 14 Sep 16

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled “High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury (SCI): Potential Mechanisms” at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting to be held September 24-28, 2016 in San Diego, CA. The presentation will be made on Tuesday, September 27, during the section on Neurotrauma and Critical Care.

Dr. Theodore said, “It has been encouraging to watch the INSPIRE study results unfold. We have amassed a wealth of knowledge and I look forward to sharing key insights with the neurosurgical community.”

In addition, Robert Heary, M.D., Director of the Spine Center at Rutgers New Jersey Medical School, will give a poster presentation titled “MR Neuroimaging Does Not Accurately Identify Intraparenchymal Cavities in the Spinal Cord Following AIS A Thoracic Spinal Cord Injuries.” The company also will engage the neurosurgical community through a steering committee meeting and an exhibitor booth.

“We look forward to interacting with and growing the network of neurosurgeons involved with our work and sharing our latest findings with the neurosurgical community at this prominent conference,” Mark Perrin, Chief Executive Officer and Chairman, said.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit

View source version on

Business Wire

Last updated on: 14/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.